Syntheses and anti-tubercular activity of β-substituted and α,β-disubstituted peptidyl β-aminoboronates and boronic acids

Journal of Peptide Science

Volumn 19, Issue 10, 2013, Pages 613-618

  Gorovoy, Alexey S ^a   Gozhina, Olga ^a   Svendsen, John Sigurd ^a   Tetz, George V ^b   Domorad, Anna ^b   Tetz, Victor V ^b   Lejon, Tore ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

^b PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Antibacterial peptides; Beta aminoboronates; Beta aminoboronic acids; Matteson homologation; Peptidyl beta aminoboronates; Peptidyl beta aminoboronic acids; Tuberculosis

Indexed keywords

ALANINE; ALPHA BETA DISUBSTITUTED PEPTIDYL BETA AMINOBORONIC ACID; ARGININE; BETA SUBSTITUTED BETA AMINOBORONIC ACID; BORONIC ACID DERIVATIVE; LYSINE; PHENYLALANINE; TRYPTOPHAN; UNCLASSIFIED DRUG;

ANTITUBERCULAR ACTIVITY; ARTICLE; CANDIDA ALBICANS; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SYNTHESIS; ESCHERICHIA COLI; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PYOGENES; TUBERCULOSIS;

MYCOBACTERIUM TUBERCULOSIS;

ANTIBACTERIAL PEPTIDES; BETA-AMINOBORONATES; BETA-AMINOBORONIC ACIDS; MATTESON HOMOLOGATION; PEPTIDYL BETA-AMINOBORONATES; PEPTIDYL BETA-AMINOBORONIC ACIDS; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; BORONIC ACIDS; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; MYCOBACTERIUM TUBERCULOSIS;

EID: 84883654057     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.2537     Document Type: Article

References (23)

1. Herzog H. History of tuberculosis. Respiration 1998; 65(1): 5-15.
2. Donoghue HD, Spigelman M, Greenblatt C, Lev-Maor LG, Bar-Gal GK, Matheson C, Vernon K, Nerlich AG and Zink AR. Tuberculosis: from prehistory to Robert Koch, as revealed by ancient DNA. Lancet Infect. Dis. 2004; 4(9): 584-592.
3. Smith NH, Hewinson RG, Kremer K, Brosch R, Gordon SV. Myths and misconceptions: the origin and evolution of Mycobacterium tuberculosis. Nat Rev Micro 2009; 7: 537-544.
4. Kaufmann SHE, Schaible UE. 100th anniversary of Robert Koch's Nobel Prize for the discovery of the tubercle bacillus. Trends Microbiol. 2005; 13: 469-475.
5. Grange JM. Effective vaccination against tuberculosis-a new ray of hope. Clin. Exp. Immunol. 2000; 120: 232-234.
6. Snell NJC. The treatment of tuberculosis: current status and future prospects. Expert Opin. Investig. Drugs 1998; 7: 545-552.
7. Asif M, Siddiqui AA, Husain A. Quinolone derivatives as antitubercular drugs. Medicinal Chemistry Research; Ahead of Print. DOI 10.1007/s00044-012-0101-3
8. David HL. Probability distribution of drug-resistant mutants in unselected populations of mycobacterium tuberculosis. Appl. Microbiol. 1970; 20: 810-814.
9. WHO (nd).Treatment of tuberculosis guidelines http://whqlibdoc.who.int/publications/2010/9789241547833_eng.pdf
10. WHO Global tuberculosis control 2011 http://www.who.int/tb/publications/global_report/2011/gtbr11_full.pdf
11. Ahmed RK, Rohava Z, Balaji KN, Hoffner SE, Gaines H, Magalhaes I, Zumla A, Skrahina A, Maeurer MJ. Pattern recognition and cellular immune responses to novel mycobacterium tuberculosis-antigens in individuals from Belarus. BMC Infectious Diseases; 2012; 12: 41.
12. Ma Z, Lienhardt C, McIlleron H, Nunn Andrew J, Wang X. Global tuberculosis drug development pipeline: the need and the reality. Lancet; 2010; 375: 2100-2109.
13. Haug BE, Svendsen, JS. The role of tryptophan in the antibacterial activity of a 15-residue bovine lactoferricin peptide. J. Pept. Sci. 2001; 7(4): 190-196.
14. Haug BE, Skar ML, Svendsen JS. Bulky aromatic amino acids increase the antibacterial activity of 15-residue bovine lactoferricin derivatives. J. Pept. Sci. 2001; 7(8): 425-432.
15. Strom MB, Haug BE, Rekdal O, Skar ML, Stensen W, Svendsen JS. Important structural features of 15-residue lactoferricin derivatives and methods for improvement of antimicrobial activity. Biochem. Cell Biol. 2002; 80(1): 65-74.
16. Haug BE, Stensen W, Stiberg T, Svendsen JS. Bulky nonproteinogenic amino acids permit the design of very small and effective cationic antibacterial peptides. J. Med. Chem. 2004; 47(17): 4159-4162.
17. Gorovoy AS, Gozhina OV, Svendsen JS, Domorad AA, Tetz GV, Tetz VV, Lejon T. Boron-containing peptidomimetics - a novel class of selective anti-tubercular drugs. Chem. Biol. Drug Des. 2012 DOI: 10.1111/cbdd.12091
18. Matteson DS, Beedle EC. A directed chiral synthesis of amino acids from boronic esters. Tetrahedron Lett. 1987; 28: 4499-4502.
19. Matteson DS, Beedle EC, Christenson E, Dewey MA, Peterson ML. A chiral synthesis of (2S, 3S)-phenylalanine-3-2H via boronic esters. J. Label. Compd. Radiopharm. 1988; 25: 675-683.
20. Bretherick L. Azide-halosolvent hazards. Chem. Eng. News 1986; 64(51): 2
21. Singh RP, Matteson DS. Asymmetric homologation of boronic esters bearing azido and silyloxy substituents. J. Org. Chem. 2000; 65: 6650-6653.
22. Gorovoy AS. Synthesis of a novel class of antitubercular peptidomimetics based on β-aminoboronates. PhD thesis, University of Tromsø 2012; 40.
23. Sewald N. Synthetic routes towards enantiomerically pure β-amino acids. Angew. Chemie, Int. Ed. 2003; 42: 5794-5795.